Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 12K | 0 | 0 | 0 | 0 |
| Gross Profit | -1M | 0 | -2K | -3K | -2K |
| Operating Income | -4M | -2K | -1M | -2M | -2M |
| EBITDA | -4M | -2K | -1M | -2M | -2M |
| Net Income | -4M | -2K | -1M | -2M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.015
-76.92% today
1Y Change
-63.89%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 254 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Voyageur Pharmaceuticals Ltd. (VYYRF) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $0.01 and down 63.9% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -71.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -71.0%, free cash flow -855.9% with operating margin -10803.3% and ROIC -477.3%. Valuation already assumes a fairly strong business story at price/sales 576.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VYYRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VYYRF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VYYRF Max Drawdown
-98.62%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VYYRF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$2.1M
-17.0% YoY
Free Cash Flow
-$2.1M
-4.2% YoY
Revenue Growth
+0.0%
EPS Growth
-71.0%
Gross Margin
-4359.0%
Net Margin
-10796.3%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 12K | 0 | 0 | 0 | 0 |
| Gross Profit | -1M | 0 | -2K | -3K | -2K |
| Operating Income | -4M | -2K | -1M | -2M | -2M |
| EBITDA | -4M | -2K | -1M | -2M | -2M |
| Net Income | -4M | -2K | -1M | -2M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 267K | 166K | 2K | 32K | 813K |
| Total Assets | 3M | 3M | 2M | 2M | 3M |
| Total Liabilities | 2M | 2M | 728K | 631K | 661K |
| Shareholder Equity | 1M | 450K | 1M | 1M | 2M |
| Total Debt | 40K | 40K | 40K | 26K | 42K |
| Net Debt | -227K | -126K | 38K | -6K | -771K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+3.8% YoY
Capital Expenditures
432K
-52.7% YoY
Free Cash Flow
2M
-4.2% YoY
Key ratios
Gross Margin
-4359.0%
Operating Margin
-10803.3%
Net Margin
-10796.3%
ROE
-313.1%
Debt / Equity
0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.